0.48
-0.0049(-1.01%)
Currency In USD
| Previous Close | 0.49 |
| Open | 0.49 |
| Day High | 0.51 |
| Day Low | 0.48 |
| 52-Week High | 662 |
| 52-Week Low | 0.36 |
| Volume | 570,851 |
| Average Volume | 11.2M |
| Market Cap | 14.04M |
| PE | 0 |
| EPS | -6,321.5 |
| Moving Average 50 Days | 0.68 |
| Moving Average 200 Days | 7.58 |
| Change | 0 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of August 19, 2025 at a share price of $0.485. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0.02 as of August 19, 2025 at a share price of $0.485.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
GlobeNewswire Inc.
Aug 11, 2025 1:00 PM GMT
Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% Istaroxime interim data was consistent with the profil
Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients
GlobeNewswire Inc.
Aug 05, 2025 1:00 PM GMT
Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials Cardiogenic shock is a severe pres
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
GlobeNewswire Inc.
Jul 29, 2025 1:01 PM GMT
Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in outstanding shares BNB coin has appreciated over 17%